These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 33493031)
1. Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure. Kosiborod M Circulation; 2021 Jan; 143(4):350-353. PubMed ID: 33493031 [No Abstract] [Full Text] [Related]
2. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus. Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357 [TBL] [Abstract][Full Text] [Related]
5. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin? Katsiki N; Triposkiadis F Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648 [No Abstract] [Full Text] [Related]
6. Empagliflozin and Major Renal Outcomes in Heart Failure. Packer M; Butler J; Zannad F; Pocock SJ; Filippatos G; Ferreira JP; Brueckmann M; Jamal W; Zeller C; Wanner C; Anker SD; N Engl J Med; 2021 Oct; 385(16):1531-1533. PubMed ID: 34449179 [No Abstract] [Full Text] [Related]
7. Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney. Grodin JL; Tang WHW Circulation; 2020 Sep; 142(11):1055-1058. PubMed ID: 32924569 [No Abstract] [Full Text] [Related]
8. Dapagliflozin (Farxiga) - a new indication for heart failure. Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023 [No Abstract] [Full Text] [Related]
9. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure? Butler J; Anker SD Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205 [No Abstract] [Full Text] [Related]
11. Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together. Carnicelli AP; Mentz RJ Circulation; 2021 Jan; 143(4):322-325. PubMed ID: 33493029 [No Abstract] [Full Text] [Related]
12. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price? Camilli M; Ballacci F; Giordano F; Minotti G J Cardiovasc Pharmacol; 2024 Jan; 83(1):43-45. PubMed ID: 37815278 [No Abstract] [Full Text] [Related]